Pay in 4 interest-free payments of $7.18 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Caution should be exercised in patients with a history of gastrointestinal disease, as Wegovy may cause adverse effects in this system
Understanding your unique genetic makeup allows for personalized strategies that align with your specific needs
The findings of this meta-analysis suggest that GLP-1 receptor agonists are not associated with an increased risk of gastrointestinal cancers and were not associated with increased gastrointestinal cancer risk and demonstrated pooled estimates below unity for colorectal and liver cancers, findings that should be interpreted as hypothesis-generating rather than confirmatory of cancer prevention (Lingvay et al., 2018
Do not share this article without checking with the recipient in advance.** In March of this year (2025), the NHS approved the GLP-1 receptor agonist Mounjaro for the treatment of obesity
Lancet Diabetes Endocrinol 2020;8:447-55
US$ 25.41
US$ 29.32
US$ 26.60
US$ 24.56
US$ 22.40
